SinoGenoMax and Clinical Data, Inc. (NASDAQ: CLDA) announced yesterday that SinoGenoMax Co. Ltd. had partnered with Clinical Data’s Cogenics division, a worldwide leader in genomics services, broadening clinical genotyping service to include the large and growing market in China. SinoGenoMax has a long and successful track record of applying a widevariety of genotyping platforms such as Re-sequencing,Taqman,SNPshot,SNPlex,DHPLC,etc. and counts among its customers servaral famous pharmaceutical companies operating in the U.S.and Europe.
"This strategic agreement between Cogenics and SinoGenoMax increases the genotyping services and geographical scope of both companies," stated Dr. Danny Ching, Chief Executive Officer of SinoGenoMax. "SinoGenoMax provides genomics-based services to both domestic and international pharmaceutical companies and this partnership represents a significant opportunity
for SinoGenoMax to widen its international spectrum."
"The extensive pharmaceutical and biotechnology infrastructure and large number of clinical trials conducted in China makethis an increasingly important market for clinical genotyping services," said Michael Lutz, Global Manager of Cogenics. "Ourpartnership with SinoGenoMax provides us with an established presence in China and an experienced international service partner who operates with similar platforms and high quality standards, thus expanding Cogenics' offering to our growing global pharmaceutical customer base."
About SinoGenoMax Co. Ltd.
SinoGenoMax Co.,Ltd. was incorporated in September 1998 and is currently located in the Beijing Economic-Technological Development Area. With its 100 employees, SinoGenoMax provides high quality and cost-effective services for local and international Universities, Research Institutes and Pharmaceutical companies. SinoGenoMax also successfully participated in large genomic research projects, such as the International Human Genome Sequencing Project, the Chinese population single nucleotide polymorphism (SNP) genotyping project, and other disease genome research projects. SinoGenoMax has operated within the ISO 9001:2000 quality management system since 2004. For more information, please visit www.sinogenomax.com/en.
About Cogenics
Cogenics, a division of Clinical Data, has established itself as a leading provider of value-based genomics solutions for both the Healthcare and Life Sciences industries. These solutions span the areas of current and next generation sequencing, gene expression, clinical and non-clinical genotyping, biomanufacturing support, nucleic acid extraction and biobanking for both research and regulated environments. Its customers include some of the world's most respected pharmaceutical and biotechnology companies, agencies of the US National Institutes of Health, leading government and academic researchers in the international life science community, and major agricultural companies and agencies. For more information, please visit www.cogenics.com.
About Clinical Data, Inc.
Clinical Data is a global biotechnology company unlocking the potential of molecular discovery, From Targeted Science to Better Healthcare(R). The Company's PGxHealth(R) division is utilizing its proprietary portfolio of biomarkers to develop and commercialize a broad range of targeted therapeutics as well as pharmacogenetic tests that help predict drug safety and efficacy, thereby reducing health care costs. Its Cogenics(R) division provides genomics services to both research and regulated environments. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide. To learn more, please visit the Company's website at www.clda.com.